Cardium Therapeutics, Inc. (Cardium) is a medical technology development-stage company. The Company is primarily focused on the development, manufacture and sale of therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium owns a portfolio of biologic growth factors and related delivery techniques, acquired from the Schering AG Group, for potential use in treating ischemic and other cardiovascular conditions. Cardium owns rights to the assets and technologies of Tissue Repair Company, a company focused on the development of growth factor therapeutics for the potential treatment of tissue wounds, such as chronic diabetic wounds. Tissue Repair Company is operated as a wholly owned subsidiary of Cardium. In July 2009, the Company completed the asset sale of its InnerCool Therapies business to Koninklijke Philips Electronics NV.

VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular and metabolic diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in Phase II clinical trials in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has agreements with Hoffmann-LaRoche Inc. and Hoffmann-LaRoche Ltd. to develop and commercialize two sets of compounds for the treatment of cardiovascular and metabolic disease.

Protein Polymer Technologies, Inc. company was founded in 1988 and is based in San Diego, California. Protein Polymer Technologies, Inc., a biotechnology company, engages in the research, development, and production of bio-active devices to improve medical and surgical outcomes. The company, through its proprietary technology, produces molecular weight polymers that can be processed into a range of material forms, such as gels, sponges, films, and fibers. It also focuses on developing protein polymers that are used in products for tissue augmentation, tissue adhesives and sealants, and drug delivery devices. The company also develops and offers surgical tissue sealants that include tissue adhesives and sealants; wound healing and tissue regeneration products, including fabric dressings, synthetic materials, and biological materials; and urethral bulking agent that relieves female stress incontinence. In addition, it develops coating technology that modifies and improves surface properties of traditional biomedical devices.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

The Italian subsidiary of Swiss drug maker Roche manufactures all of the company's most successful medications -- hepatitis B and C drug Pegasys, cancer drugs Herceptin and Avastin, and MabThera, for non-Hodgkin lymphoma. Roche S.p.A.'s business is roughly 40% oncology and hematology, 30% specialty care (Pegasys, Neorecormon, Copegus), and 30% primary care (analgesics, antibiotics). Its 700,000-square-foot production facility in Segrate, a town near Milan in northern Italy, produces almost 1,400 tons of medication every year, about 60% of which is exported across Europe.

Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. It develops, produces, markets, and distributes therapies for the people suffering from chronic and acute, immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. The company's products include Gamunex, an intravenous immune globulin (IGIV) for the treatment of primary immune deficiency and autoimmune diseases; and Prolastin, an alpha-1 proteinase inhibitor (A1PI) for the treatment of alpha-1 antitrypsin deficiency-related emphysema. It also offers Hypermunes, which are antibody preparations for hepatitis, rabies, tetanus, and treatment of Rh negative women pregnant with Rh positive children; and albumin under various brand names, including Plasbumin albumin and Plasmanate plasma protein factor. Talecris Biotherapeutics Holdings Corp. is headquartered in Research Triangle Park, North Carolina.

Schiff Nutrition International, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah. Schiff Nutrition International, Inc. develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. The Company offers a range of capsules, tablets and nutrition bars. Its portfolio of brands includes Schiff, Move Free, MegaRed and Tiger’s Milk, which is marketed through the mass market, including club and health food store distribution channels. The Company markets a range of specialty supplements, vitamins and minerals under the Schiff brand. The Schiff brand specialty supplements are designed to provide consumers with targeted support for their wellness efforts. Its specialty supplements include joint care products marketed under the Schiff brand, including its Move Free and Glucosamine products. Its Move Free product is one of the joint care products in the mass market channel.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Biogen Idec Inc. company was founded in 1985 and is based in Cambridge, Massachusetts. Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), crohn’s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Transition Therapeutics Inc. was founded in 1987 and is based in Toronto, Canada. Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada. Its lead products include ELND-005/AZD-103, a Phase II clinical trial product for the treatment of Alzheimer's disease; and TT-223 gastrin analogue, a Phase II clinical trial product for the treatment of diabetes. The company's TT-223 gastrin analogue, includes TT-223 in combination with a GLP-1 analogue as a therapy for the treatment of type 1 and type 2 diabetes, which is under Phase 1b clinical study in type 2 diabetes patients; and TT-223 in combination with EGF analogues that has completed two Phase I clinical trials for the drug candidate in type 1 and type 2 diabetics. In addition, it has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition Therapeutics Inc. has a strategic collaboration with Elan Pharma International Limited to develop and commercialize ELND-005/AZD-103 therapeutic agent, as well as a licensing and collaboration agreement with Eli Lilly and Company to develop and commercialize gastrin based therapies, including the lead compound TT-223. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. in December 2000.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.